MLMengtong Li

Mengtong Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mengtong Li has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Jiayi Liu

    Department of Neurosurgery , The Affiliated Hospital of Qingdao University , Qingdao , Shandong , China , qdu.edu.cn

    1 shared publication
  • Peng Lun

    Department of Neurosurgery, the Affiliated Hospital of Qingdao University, Qingdao, China

    1 shared publication
  • Xia Liu

    Affiliated Hospital of Qingdao University, 16 Jiangsu Road, Qingdao, 266000, China, 1 18661807007, 1 053282911

    1 shared publication
  • Zichen Liu

    Department of Neurosurgery , The Affiliated Hospital of Qingdao University , Qingdao , Shandong , China , qdu.edu.cn

    1 shared publication

Latest Publications

  • Open Access

    A Propionate Metabolism‐Based Gene Signature Reveals Immunogenomic and Transcriptomic Determinants of Prognosis in Glioblastoma Through Multiomics Integration

    by Mengtong Li, Jiayi Liu, Zichen Liu, Xia Liu, Peng Lun

    Glioblastoma (GBM) remains a lethal brain tumor with limited prognostic tools. Metabolic reprogramming, particularly in understudied pathways like propionate metabolism, may offer new biomarkers. Here, we identified a novel prognostic signature based on seven propionate metabolism‐related genes (SLC9A1, ELANE, ACADS, SOAT2, MYD88, ADSL, and BMP2) from the TCGA‐GBM cohort. A risk scoring model was constructed via LASSO Cox regression effectively stratified patients into high‐ and low‐risk groups with significant survival differences, which was also validated in independent GEO datasets. Multiomics analysis revealed that the high‐risk group was associated with an immunosuppressive microenvironment, characterized by increased immune checkpoint expression and distinct immune cell infiltration. Mutational profiling showed a strong association with key driver alterations, including enrichment of RB1 mutations in high‐risk and IDH1 mutations in low‐risk patients. Single‐cell RNA‐seq (scRNA‐seq) analysis confirmed the specific enrichment of signature genes within malignant cells, and coexpression network analysis (hdWGCNA) further linked the high‐risk phenotype to transcriptional modules. In conclusion, we established and validated a robust metabolic gene signature that not only predicts prognosis but also delineates a high‐risk GBM subtype defined by integrated metabolic, immunogenomic, and transcriptional features, providing new insights into the determinants of GBM aggressiveness.